BETHESDA, Md. A Food and Drug Administration advisory committee has voted to recommend expanding the use of an Eli Lilly & Co. pain drug, the drug maker said Thursday.
Lilly said the FDA’s Anesthetic and Life Support Drugs Advisory Committee voted to recommend approval of Cymbalta (duloxetine hydrochloride) as a treatment for chronic lower back pain, though it did not support the drug as a treatment for chronic pain due to osteoarthritis. The drug currently is approved for treating diabetic peripheral neuropathic pain and fibromyalgia.
The advisory committee’s vote does is not binding, though the FDA will take it into account when deciding whether to approve the new uses for the drug.